The local medical community is excited with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor showing significant results in clinical trials for addressing obesity. This treatment suggests a https://agendabookmarks.com/story21714554/retatrutide-australia-australia-a-new-prospect-for-weight-management